A Phase 1 Study of a CDK 4/6 Dual Inhibitor in Patients With Advanced Cancer

Trial Profile

A Phase 1 Study of a CDK 4/6 Dual Inhibitor in Patients With Advanced Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 May 2017

At a glance

  • Drugs Abemaciclib (Primary) ; Fulvestrant
  • Indications Advanced breast cancer; Cancer; Colorectal cancer; Glioblastoma; Lymphoma; Male breast cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Eli Lilly
  • Most Recent Events

    • 20 Mar 2017 Planned End Date changed from 1 Apr 2017 to 3 Apr 2018.
    • 15 Mar 2016 Planned End Date changed from 1 Apr 2016 to 1 Oct 2016 as reported by ClinicalTrials.gov.
    • 08 Oct 2015 According to an Eli Lilly media release, U.S. FDA has granted breakthrough therapy designation to abemaciclib based on data from the breast cancer cohort expansion of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top